1.17
前日終値:
$1.18
開ける:
$1.18
24時間の取引高:
3.00M
Relative Volume:
0.91
時価総額:
$255.91M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.5519
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
+10.38%
1か月 パフォーマンス:
-24.03%
6か月 パフォーマンス:
-52.82%
1年 パフォーマンス:
-52.44%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
名前
Allogene Therapeutics Inc
セクター
電話
(650) 457-2700
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ALLO
Allogene Therapeutics Inc
|
1.17 | 231.85M | 95,000 | -327.27M | -239.25M | -2.12 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
2025-03-14 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
2024-08-08 | 再開されました | Oppenheimer | Outperform |
2024-05-31 | 開始されました | Piper Sandler | Overweight |
2024-01-05 | ダウングレード | Guggenheim | Buy → Neutral |
2024-01-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-08 | 開始されました | Citigroup | Buy |
2023-06-26 | 再開されました | Oppenheimer | Outperform |
2023-03-21 | 開始されました | Bernstein | Mkt Perform |
2023-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
2023-01-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
2022-12-12 | ダウングレード | BofA Securities | Buy → Underperform |
2022-08-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2022-07-15 | アップグレード | Goldman | Neutral → Buy |
2022-06-03 | 開始されました | Robert W. Baird | Neutral |
2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
2021-10-20 | 開始されました | Cowen | Outperform |
2021-10-08 | ダウングレード | Goldman | Buy → Neutral |
2021-10-08 | ダウングレード | Stifel | Buy → Hold |
2021-09-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
2021-06-21 | 再開されました | Jefferies | Buy |
2021-05-20 | アップグレード | Truist | Hold → Buy |
2021-05-14 | 開始されました | B. Riley Securities | Buy |
2021-01-26 | アップグレード | Stifel | Hold → Buy |
2020-12-10 | 再開されました | H.C. Wainwright | Buy |
2020-11-24 | 開始されました | BofA Securities | Buy |
2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
2020-06-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-05-29 | 繰り返されました | H.C. Wainwright | Buy |
2020-05-19 | アップグレード | ROTH Capital | Neutral → Buy |
2020-05-15 | アップグレード | Guggenheim | Neutral → Buy |
2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-05-14 | ダウングレード | SunTrust | Buy → Hold |
2020-04-13 | 開始されました | SunTrust | Buy |
2020-03-13 | 開始されました | H.C. Wainwright | Buy |
2020-03-05 | 開始されました | Stifel | Hold |
2020-02-24 | 開始されました | Berenberg | Hold |
2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
2019-11-04 | 開始されました | Canaccord Genuity | Buy |
2019-08-09 | 開始されました | BTIG Research | Buy |
2019-06-05 | 開始されました | ROTH Capital | Neutral |
2019-05-31 | 開始されました | Guggenheim | Neutral |
2019-05-23 | 開始されました | Stifel | Hold |
2019-03-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus
Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - marketscreener.com
Breakthrough in Solid Tumors: ALLO-316 CAR T Therapy Achieves 12-Month Remission in Advanced Kidney Cancer - Stock Titan
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada
Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com
Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia
Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times
Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq
Breakthrough: First-Ever Allogeneic CAR T Therapy Shows Efficacy Against Solid Tumors in Kidney Cancer Trial - Stock Titan
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus
ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timeline Delays | ALLO Stock News - GuruFocus
Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timel - GuruFocus
Allogene Therapeutics (ALLO) Price Target Lowered by Truist Securities | ALLO Stock News - GuruFocus
Allogene Therapeutics (ALLO) Stock Drops Amid Trial Delays - GuruFocus
RBC Capital Reiterates Outperform Rating for Allogene Therapeuti - GuruFocus
Allogene Therapeutics (ALLO) Downgraded by Citizens JMP | ALLO S - GuruFocus
Piper Sandler Lowers Price Target for Allogene Therapeutics (ALL - GuruFocus
Allogene Therapeutics stock falls on trial delay, downgrade - Seeking Alpha
Allogene Therapeutics (ALLO): Price Target Lowered by Analyst | - GuruFocus
Piper Sandler Lowers Price Target for Allogene Therapeutics (ALLO) | ALLO Stock News - GuruFocus
Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating - marketscreener.com
Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer - GuruFocus
Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer | ALLO Stock News - GuruFocus
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Allogene (ALLO) Pioneers Future of Cell Therapy with Innovative Strategies | ALLO Stock News - GuruFocus
Truist Lowers Price Target for Allogene Therapeutics (ALLO) Amid Trial Delays | ALLO Stock News - GuruFocus
Allogene Therapeutics (ALLO) Target Price Adjusted by Oppenheimer | ALLO Stock News - GuruFocus
Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating - marketscreener.com
Allogene Therapeutics (ALLO) Sees Price Target Reduction by Anal - GuruFocus
Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer - TipRanks
Allogene Therapeutics Inc (ALLO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):